Table 4.
Total reimbursements (euros) in 2016 for several gastrointestinal therapeutic drug classes and mean cost per individual with at least one reimbursement, by sex, age, diseases or other health conditions.
| Gastrointestinal therapeutic drug classes | Mean per individual |
Total |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| A02A | A02BC | A02BX | A02X | A03 | A04 | A06 | A07 | All | All | |
|
n individuals with at least one
reimbursement for the class (million) |
0.86 | 13.9 | 2.6 | 3.3 | 11.5 | 4.1 | 5.9 | 5.8 | 25.7 | |
| Total reimbursement (€ million) | 2.6 | 422.7 | 11.3 | 8.1 | 47.4 | 59.1 | 71.7 | 76.0 | 706.9 | |
| All | 3 | 30 | 4 | 2 | 4 | 14 | 12 | 13 | 28 | 706.9 |
| Sex | ||||||||||
| Men | 3 | 32 | 5 | 3 | 4 | 15 | 12 | 14 | 28 | 296.7 |
| Women | 3 | 29 | 4 | 2 | 4 | 14 | 12 | 12 | 27 | 410.3 |
| Age (year) | ||||||||||
| 00–01 | 1 | 33 | 4 | 2 | 1 | 1 | 2 | 5 | 9 | 5.9 |
| 02–09 | 1 | 28 | 3 | 2 | 1 | 1 | 4 | 3 | 5 | 10.7 |
| 10–17 | 1 | 9 | 1 | 2 | 1 | 2 | 4 | 4 | 5 | 7.5 |
| 18–34 | 2 | 10 | 3 | 2 | 3 | 3 | 6 | 9 | 11 | 47.6 |
| 35–54 | 2 | 19 | 3 | 2 | 4 | 15 | 10 | 18 | 22 | 145.8 |
| 55–64 | 3 | 32 | 5 | 3 | 6 | 45 | 13 | 23 | 38 | 139.8 |
| 65–74 | 4 | 43 | 6 | 4 | 8 | 69 | 15 | 25 | 49 | 162.4 |
| 75 and older | 5 | 55 | 7 | 5 | 11 | 38 | 18 | 23 | 57 | 187.2 |
| Diseases and other health conditions | ||||||||||
| None | 1 | 10 | 2 | 2 | 1 | 1 | 4 | 3 | 6 | 61.5 |
| Cardiovascular and cerebrovascular disease | 5 | 62 | 8 | 5 | 11 | 54 | 18 | 25 | 68 | 182.1 |
| Cardiovascular prevention (pharmacological)* | 3 | 40 | 5 | 3 | 7 | 36 | 15 | 22 | 43 | 197.0 |
| Diabetes | 6 | 56 | 9 | 5 | 11 | 45 | 18 | 22 | 61 | 124.8 |
| Cancers | 6 | 49 | 9 | 7 | 14 | 176 | 18 | 27 | 85 | 148.2 |
| Mental illness | 6 | 50 | 9 | 4 | 12 | 23 | 25 | 21 | 57 | 73.9 |
| Psychotropic drug treatments** | 4 | 48 | 6 | 4 | 9 | 42 | 18 | 22 | 56 | 203.6 |
| Dementia and neurological disease | 7 | 57 | 10 | 5 | 15 | 26 | 27 | 23 | 62 | 53.2 |
| Chronic respiratory diseases | 5 | 50 | 7 | 3 | 8 | 27 | 17 | 16 | 52 | 106.2 |
| Chronic inflammatory bowel disease | 8 | 45 | 9 | 10 | 22 | 27 | 14 | 357 | 276 | 49.3 |
| HIV or AIDS | 7 | 34 | 12 | 5 | 11 | 33 | 16 | 24 | 43 | 2.8 |
| End-stage renal disease | 10 | 83 | 19 | 9 | 19 | 37 | 25 | 28 | 98 | 6.2 |
| Liver or pancreas diseases | 6 | 52 | 9 | 6 | 13 | 84 | 20 | 38 | 75 | 26.3 |
| LTDs nonincluded elsewhere | 7 | 57 | 10 | 5 | 14 | 34 | 23 | 32 | 65 | 60.7 |
| Pregnancy | 3 | 13 | 5 | 2 | 6 | 6 | 5 | 11 | 15 | 12.8 |
| Nonsteroidal anti-inflammatory drugs° | 2 | 23 | 3 | 2 | 3 | 2 | 7 | 4 | 22 | 4.2 |
| Corticosteroid treatment° | 2 | 27 | 3 | 2 | 2 | 2 | 7 | 7 | 20 | 0.4 |
| Analgesic drug treatment° | 2 | 19 | 3 | 2 | 2 | 1 | 6 | 4 | 14 | 15.9 |
A02A: antacids; A02BC: PPIs; A02BX: other drugs for peptic ulcer and gastro-oesophageal reflux disease; A02X: other drugs for acid-related disorders; A03: drugs for functional gastrointestinal disorders; A04: antiemetics and antinauseants, A06: drugs for constipation, A07: antidiarrhoeals, intestinal anti-inflammatory/anti-infective agents.
Excluding: ischaemic heart disease, cerebrovascular disease, heart failure, peripheral vascular disease, diabetes, end-stage renal disease.
Excluding: mental illness.
People with at least six reimbursements per year and without diseases, other chronic treatments or pregnancy during the year.
AIDS, acquired immunodeficiency syndrome; HIV, human immunodeficiency virus; LTD, long-term chronic disease; PPIs, proton-pump inhibitors.